In recent decades, the PML–RARA fusion-induced AML has become highly curable since the broad application of target chemotherapy drugs, all-trans retinoic acid and arsenic trioxide, into clinical use (Wang and Chen., 2008). This evidence concerns the gene RARA and acute myeloid leukemia.